Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for HYDROXYPROGESTERONE CAPROATE
- Effect of Progesterone on Latent Phase Prolongation in Patients With Preterm Premature Rupture of Membranes
- Gonadotropin Releasing Hormone Agonist (GnRHa) Versus Estrogen and Progesterone for Luteal Support in High Responders
- Effects of E2, P4 and LH Levels on the Day of Transfer and Endometrial Cavity Thickness on Implantation Success in Patients With Frozen-thawed Embryo Transfer Cycle
- Progesterone in Expectantly Managed Early-onset Preeclampsia
- Vaginal Progesterone Versus 17-Alpha-Hydroxyprogesterone Caproate in Placenta Previa
- 17-Alpha-Hydroxyprogesterone Caproate in Pregnant Women With Placenta Previa
- 17OHP-C Dosing Among Obese Pregnant Women
- Improving Pregnancy Outcomes With Progesterone
- Relationship Between Plasma Concentration of Hydroxyprogesterone Caproate (17-OHPC) and Preterm Birth
- Intramuscular Hydroxyprogesterone Caproate and Placenta Previa
- Comparing Bioavailability When Preservative-free Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) is Administered as an Intramuscular Manual Injection or as a Subcutaneous Injection Using an Auto-injector in Healthy Post-menopausal Women
- Study Assessing Injection Pain of Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) When Administered Via Subcutaneous Auto-injector vs Intramuscular Injection Via Needle and Syringe in Healthy Post-menopausal Women
- Vaginal Versus Intramuscular Progesterone for the Prevention of Recurrent Preterm Birth
- Pharmacokinetic Study of Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) and Its Metabolites in Blood
- Prevention of Preterm Labor in Patients With a Previous Episode of Threatened Preterm Labor With Progesterone
- A Prospective, Noninterventional Follow-Up Study of Children Aged 23 to 25 Months, Born to Mothers Who Received Hydroxyprogesterone Caproate Injection, 250 mg/mL, or Vehicle for Prevention of Preterm Birth
- Progesterone (17P, Makena®) for Prolongation of Pregnancy in Women With Preterm Rupture of the Membranes (PROM)
- Progesterone for the Management of Preterm, Premature Rupture of the Membranes: A Randomized Controlled Trial.
- Confirmatory Study of 17P vs Vehicle for Prevention of Preterm Birth in Women w/ Previous Spontaneous Preterm Delivery
- The Use of Progesterone to Reduce Preterm Birth
- 17 Alfa Hydroxyprogesterone Caproate Versus Natural Progesterone for the Prevention of Preterm Labor
- A Randomized Trial of Cerclage Versus 17 α-Hydroxyprogesterone Caproate for Treatment of a Short Cervix
- Comparing IM vs. Vaginal Progesterone for Pre-term Birth
- RCT of Progesterone to Prevent Preterm Birth in Nulliparous Women With a Short Cervix
- Study of Pharmacology of 17-OHPC in Pregnancy
- 17OHP for Reduction of Neonatal Morbidity Due to Preterm Birth (PTB) in Twin and Triplet Pregnancies
- Prevention of Preterm Delivery in Twin Pregnancies by 17 Alpha-hydroxyprogesterone Caproate
- Omega-3 Fatty Acid Supplementation to Prevent Preterm Birth in High Risk Pregnancies
- Treatment of Preterm Labor With 17 Alpha-hydroxyprogesterone Caproate
- Trial of Progesterone in Twins and Triplets to Prevent Preterm Birth (STTARS)
Clinical trials list
click for details